Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1451 to 1500 of 1834 results for carers

  1. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  2. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

    Technology appraisal guidance
    Discontinued

  3. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued Reference number: GID-TA11188

    Technology appraisal guidance
    Discontinued

  4. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued Reference number: GID-TA11206

    Technology appraisal guidance
    Discontinued

  5. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

    Technology appraisal guidance
    Discontinued

  6. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

    Technology appraisal guidance
    Discontinued

  7. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

    Technology appraisal guidance
    Discontinued

  8. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued

  10. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued

  11. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  12. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  14. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

    Medical technologies guidance
    In development

  18. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development Reference number: GID-TA11523 Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

    HealthTech guidance
    Published
    21 October 2024
    View recommendations

    Sections for HTG729

  22. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

    HealthTech guidance
    Published
    22 January 2026
    View recommendations

    Sections for HTG768

  23. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued Reference number: GID-TA11522

    Technology appraisal guidance
    Discontinued

  24. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

    In development Reference number: GID-TA11679 Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. History of NICE

    expertise of the royal medical colleges, professional bodies and patient/carer organisations. 2002 First clinical guideline CG1...

  26. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development Reference number: GID-TA11302 Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]

    In development Reference number: GID-TA11377 Expected publication date: TBC

    Technology appraisal guidance
    In development

  31. What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared with other psychological therapies in children aged 5 to 11 years and young people aged 12 to 18 years with mild or moderate to severe depression?

    ensure that children and young people with depression and their families or carers (as appropriate) receive the best possible care and...

    Research recommendation
    Published
    25 October 2019

  32. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of supported digital cognitive–behavioural therapy (CBT) compared with unsupported digital CBT in young people aged 12 to 18 years with mild depression, and what are the key components of the interventions that influence effectiveness?

    ensure that children and young people with depression and their families or carers (as appropriate) receive the best possible care and...

    Research recommendation
    Published
    25 October 2019

  33. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development Reference number: GID-TA10899 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Emphysema - inhaled alpha-1 antitrypsin [ID1200]

    Discontinued Reference number: GID-TA11179

    Technology appraisal guidance
    Discontinued

  35. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]

    In development Reference number: GID-TA11629 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST24

  37. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)

    Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    31 January 2024
    View recommendations

    Sections for TA947

  38. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

    Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.

    Technology appraisal guidance
    Published
    2 July 2025
    View recommendations

    Sections for TA1077

  39. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

    Technology appraisal guidance
    Discontinued

  40. Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  43. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

    Quality standard
    Last updated
    3 September 2025
    View quality statements

    Sections for QS9

  44. Trauma (QS166)

    This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 March 2018
    View quality statements

    Sections for QS166

  45. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  46. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued Reference number: GID-TA11176

    Technology appraisal guidance
    Discontinued

  47. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

    Technology appraisal guidance
    Discontinued

  48. Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

    In development Reference number: GID-TA11745 Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  50. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA892